Current drug therapy and pharmaceutical challenges for Chagas disease

Acta Tropica

Volumn 156, Issue , 2016, Pages 1-16

  Bermudez, José ^a   Davies, Carolina ^a   Simonazzi, Analía ^a   Pablo Real, Juan ^b   Palma, Santiago ^b  

^a UNIVERSIDAD NACIONAL DE SALTA   (Argentina)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Benznidazol; Chagas disease; New medication; Nifurtimox; Trypanocidal treatment; Trypanosoma cruzi

Indexed keywords

1,10 PHENANTHROLINE; BAFILOMYCIN B1; BENZNIDAZOLE; BISPHOSPHONIC ACID DERIVATIVE; CHROMOMYCIN A3; CLOFAZIMINE; CLOMIPRAMINE; CRUZIPAIN; DACTINOMYCIN; DEHYDROLEUCODINE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; ECHINOMYCIN; ERGOSTEROL; ESSENTIAL OIL; HELENALIN; HYGROLIDIN; NIFURTIMOX; NITROFURAL; NITROREDUCTASE; NITROREDUCTASE TYPE I; NONACTIN; NORFLOXACIN; PLANT MEDICINAL PRODUCT; SESQUITERPENE LACTONE; SIALIDASE; SPARFLOXACIN; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; ANTITRYPANOSOMAL AGENT; NITROIMIDAZOLE DERIVATIVE;

CHAGAS DISEASE; DISEASE TREATMENT; DRUG; INFECTIOUS DISEASE; RESEARCH; TOXICITY;

ANTIPROTOZOAL ACTIVITY; CHAGAS DISEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION CONTROL; MEDICAL INFORMATION; MEDICAL RESEARCH; PATIENT CARE; PROTEIN FUNCTION; PROTEIN TARGETING; PUBLIC HEALTH SERVICE; PUBLICATION; REVIEW; STEROL SYNTHESIS; TOTAL QUALITY MANAGEMENT; TREATMENT INDICATION; DRUG EFFECTS; LIFE CYCLE STAGE; TRYPANOSOMA CRUZI; WESTERN HEMISPHERE;

HEXAPODA; MAMMALIA; PROTOZOA; REDUVIIDAE; TRYPANOSOMA CRUZI;

AMERICAS; CHAGAS DISEASE; HUMANS; LIFE CYCLE STAGES; NIFURTIMOX; NITROIMIDAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84953853524     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2015.12.017     Document Type: Review

References (192)

1. Organization WH. Chagas disease (American trypanosomiasis) 2015. Updated March 2015. Available from: . http://www.who.int/mediacentre/factsheets/fs340/en/.
2. AGB. Support for Neglected Tropical Diseases 2015 [cited 2015 November 18]. Available from: . http://www.bayer.com/en/chagas-and-african-sleeping-sickness.aspx.
3. Abe F., Yamauchi T., Nagao T., Kinjo J., Okabe H., Higo H., et al. Ursolic acid as a trypanocidal constituent in rosemary. Biol. Pharm. Bull. 2002, 25(11):1485-1487.
4. Agustí R., París G., Ratier L., Frasch A.C., de Lederkremer R.M. Lactose derivatives are inhibitors of Trypanosoma cruzi trans-sialidase activity toward conventional substrates in vitro and in vivo. Glycobiology 2004, 14(7):659-670.
5. Aleixo D.L., Ferraz F.N., Ferreira É.C., de Lana M., Gomes M.L., de Abreu Filho B.A., et al. Highly diluted medication reduces parasitemia and improves experimental infection evolution by Trypanosoma cruzi. BMC Res. Notes 2012, 5:352. PubMed PMID: PMC3441236.
6. Alonso-Vega C., Billot C., Torrico F. Achievements and challenges upon the implementation of a program for national control of congenital Chagas in Bolivia: results 2004-2009. PLoS Negl. Trop. Dis. 2013, 7(7):e2304. PubMed PMID: PMC3708826.
7. Alvarez M., Vigliano C., Lococo B., Petti M., Bertocchi G., Viotti R. Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease. Trans. R. Soc. Trop. Med. Hyg. 2012, 106(10):636-638.
8. Andrade S.G., Magalhães J.B., Pontes A.L. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types. Bull. World Health Org. 1985, 63(4):721-726. PubMed PMID: PMC2536372.
9. Annang F., Pérez-Moreno G., García-Hernández R., Cordon-Obras C., Martín J., Tormo J.R., et al. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human african trypanosomiasis, leishmaniasis, and chagas disease. J. Biomol. Screen. 2015, 20(January (1)):82-91.
10. Anon Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J. Exp. Med. 1992, 175(1):169-174. PubMed PMID: PMC2119081.
11. Apt W., Aguilera X., Arribada A., Pérez C., Miranda C., Sánchez G., et al. Treatment of chronic Chagas' disease with itraconazole and allopurinol. Am. J. Trop. Med. Hyg. 1998, 59(1):133-138.
12. Apt W., Arribada A., Zulantay I., Sanchez G., Vargas S., Rodriguez J. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up. Ann. Trop. Med. Parasitol. 2003, 97(1):23-29.
13. Apt W., Arribada A., Zulantay I., Rodríguez J., Saavedra M., Muñoz A. Treatment of Chagas' disease with itraconazole: electrocardiographic and parasitological conditions after 20 years of follow-up. J. Antimicrob. Chemother. 2013, 68(9):2164-2169.
14. Assíria Fontes Martins T., de Figueiredo Diniz L., Mazzeti A.L., da Silva do Nascimento Á.F., Caldas S., Caldas I.S., et al. Benznidazole/itraconazole combination treatment enhances anti-Trypanosoma cruzi activity in experimental chagas disease. PLoS One 2015, 10(6):e0128707. PubMed PMID: PMC4468053.
15. Aufderheide A.C., Salo W., Madden M., Streitz J., Buikstra J., Guhl F., et al. A 9000-year record of Chagas' disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(7):2034-2039.
16. Barbosa C.F., Okuda E.S., Chung M.C., Ferreira E.I., Cicarelli R.M.B. Rapid test for the evaluation of the activity of the prodrug hydroxymethylnitrofurazone in the processing of Trypanosoma cruzi messenger RNAs. Braz. J. Med. Biol. Res. 2007, 40:33-39.
17. Barbosa M.P.T., Carmo A.A.L.D., Rocha M.O.D.C., Ribeiro A.L.P. Ventricular arrhythmias in Chagas disease. Rev. Soc. Bras. Med. Trop. 2015, 48:4-10.
18. Barreto-de-Albuquerque J., Silva-dos-Santos D., Pérez A.R., Berbert L.R., de Santana-van-Vliet E., Farias-de-Oliveira D.A., et al. Trypanosoma cruzi Infection through the oral route promotes a severe infection in mice: new disease form from an old infection?. PLoS Neglect. Trop. Dis. 2015, 9(6):e0003849. PubMed PMID: PMC4474863.
19. Batista D.d.G.J., da Silva P.B., Lachter D.R., Silva R.S., Aucelio R.Q., Louro S.R.W., et al. Manganese(II) complexes with N4-methyl-4-nitrobenzaldehyde, N4-methyl-4-nitroacetofenone, and N4-methyl-4-nitrobenzophenone thiosemicarbazone: Investigation of in vitro activity against Trypanosoma cruzi. Polyhedron 2010, 29(10):2232-2238.
20. Batista D.D.G.J., da Silva P.B., Stivanin L., Lachter D.R., Silva R.S., Felcman J., et al. Co(II), Mn(II) and Cu(II) complexes of fluoroquinolones: synthesis, spectroscopical studies and biological evaluation against Trypanosoma cruzi. Polyhedron 2011, 30(10):1718-1725.
21. Bazán P., Lo Presti M., Rivarola H., Triquell M., Fretes R., Fernández A., et al. Chemotherapy of chronic indeterminate Chagas disease: a novel approach to treatment. Parasitol. Res. 2008, 103(3):663-669. English.
22. Bellera C.L., Balcazar D.E., Vanrell M.C., Casassa A.F., Palestro P.H., Gavernet L., et al. Computer-guided drug repurposing: Identification of trypanocidal activity of clofazimine, benidipine and saquinavir. Eur. J. Med. Chem. 2015, 93:338-348.
23. Benvenuti L., Roggério A., Freitas H., Mansur A., Fiorelli A., Higuchi M. Chronic American trypanosomiasis: parasite persistence in endomyocardial biopsies is associated with high-grade myocarditis. Ann. Trop. Med. Parasitol. 2008, 102(6):481-487.
24. Bern C. Chagas' disease. New Engl. J. Med. 2015, 373(November 19):1882. PubMed PMID: 26535522. Epub 2015/11/05. eng.
25. Bodley A.L., Shapiro T.A. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(9):3726-3730. PubMed PMID: PMC42034.
26. Borges AR, de Albuquerque Aires JR, Higino TMM, de Medeiros MdGF, Citó AMdGL, Lopes JAD, et al. Trypanocidal and cytotoxic activities of essential oils from medicinal plants of Northeast of Brazil. Experimental parasitology. 2012; 132(2): 123-128.
27. Bot C., Hall B.S., Bashir N., Taylor M.C., Helsby N.A., Wilkinson S.R. Trypanocidal activity of aziridinyl nitrobenzamide prodrugs. Antimicrob. Agents Chemother. 2010, 54(10):4246-4252.
28. Bou D.D., Tempone A.G., Pinto É.G., Lago J.H.G., Sartorelli P. Antiparasitic activity and effect of casearins isolated from Casearia sylvestris on Leishmania and Trypanosoma cruzi plasma membrane. Phytomedicine 2014, 21(5):676-681.
29. Boyraz N., Özcan M. Inhibition of phytopathogenic fungi by essential oil, hydrosol, ground material and extract of summer savory (Satureja hortensis L.) growing wild in Turkey. Int. J. Food Microbiol. 2006, 107(3):238-242.
30. Brenière S.F., Morochi W., Bosseno M.-F., Ordoñez J., Gutierrez T., Vargas F., et al. Trypanosoma cruzi genotypes associated with domestic Triatoma sordida in Bolivia. Acta Trop. 1998, 71(3):269-283.
31. Buchini S., Buschiazzo A., Withers S.G. A new generation of specific Trypanosoma cruzi trans-sialidase inhibitors. Angew. Chem. 2008, 120(14):2740-2743.
32. Buckner F.S., Wilson A.J., White T.C., Van Voorhis W.C. Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob. Agents Chemother. 1998, 42(12):3245-3250.
33. Buckner F.S., Bahia M.T., Suryadevara P.K., White K.L., Shackleford D.M., Chennamaneni N.K., et al. Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob. Agents Chemother. 2012, 56(9):4914-4921.
34. Buckner F.S. Experimental chemotherapy and approaches to drug discovery for Trypanosoma cruzi infection. Advances in Parasitology 2011, vol. 75:89-119. Academic Press, Chapter 5.
35. Buschiazzo A, Amaya MaF, Cremona MaL, Frasch AC, Alzari PM. The Crystal Structure and Mode of Action of trans-Sialidase, a Key Enzyme in Trypanosoma cruzi Pathogenesis. Molecular Cell. 2002; 10(4): 757-768.
36. Buschiazzo A., Muiá R., Larrieux N., Pitcovsky T., Mucci J., Campetella O. Trypanosoma cruzi trans-sialidase in complex with a neutralizing antibody: structure/function studies towards the rational design of inhibitors. PLoS Pathog. 2012, 8(1):e1002474.
37. Bustamante J.M., Craft J.M., Crowe B.D., Ketchie S.A., Tarleton R.L. New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J. Infect. Dis. 2014, 209(1):150-162.
38. Camandaroba E.L., Pinheiro Lima C.M., Andrade S.G. Oral transmission of Chagas disease: importance of Trypanosoma cruzi biodeme in the intragastric experimental infection. Rev. Inst. Med. Trop. Sao Paulo 2002, 44(March-April (2)):97-103. PubMed PMID: 12048547. Epub 2002/06/06. eng.
39. Camandaroba E.L., Reis E.A., Gonçalves M.S., Reis M.G., Andrade S.G. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Rev. Soc. Bras. Med. Trop. 2003, 36(2):201-209.
40. Campetella O., Henriksson J., Åslund U., Frasch A.C.C., Pettersson U., Cazzulo J.J. The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is encoded by multiple polymorphic tandemly organized genes located on different chromosomes. Mol. Biochem. Parasitol. 1992, 50(2):225-234.
41. Campos M.C.O., Castro-Pinto D.B., Ribeiro G.A., Berredo-Pinho M.M., Gomes L.H.F., da Silva Bellieny M.S., et al. P-glycoprotein efflux pump plays an important role in Trypanosoma cruzi drug resistance. Parasitol. Res. 2013, 112(6):2341-2351. PubMed PMID: PMC3663987.
42. Campos M.C.O., Leon L.L., Taylor M.C., Kelly J.M. Benznidazole-resistance in Trypanosoma cruzi: evidence that distinct mechanisms can act in concert. Mol. Biochem. Parasitol. 2014, 193(1):17-19. PubMed PMID: PMC3988956.
43. Cardoso A.V., Lescano S.A., Amato Neto V., Gakiya É., Santos S.V. Survival of Trypanosoma cruzi in sugar cane used to prepare juice. Rev. Inst. Med. Trop. Sao Paulo 2006, 48(5):287-289.
44. Cardozo R.M., Panzera F., Gentile A.G., Segura M.A., Pérez R., Díaz R.A., et al. Inheritance of resistance to pyrethroids in Triatoma infestans, the main Chagas disease vector in South America. Genet. Evol. 2010, 10(8):1174-1178.
45. Castellanos-Domínguez Y.Z., Cucunubá Z.M., Orozco L.C., Valencia-Hernández C.A., León C.M., Florez A.C., et al. Risk factors associated with Chagas disease in pregnant women in Santander, a highly endemic Colombian area. Trop. Med. Int. Health 2015.
46. Castro J., Diaz D.T.E. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). BES 1988, 1(1):19-33.
47. Cazzulo J. Proteinases of Trypanosoma cruzi: potential targets for the chemotherapy of Chagas disease. Curr. Top. Med. Chem. 2002, 2(11):1261-1271.
48. ® in mice infected with Trypanosoma cruzi strains. Int. J. Antimicrob. Agents 2012, 40(6):527-532.
49. Cerecetto H., Porcal W. Pharmacological properties of furoxans and benzofuroxans: recent developments. Mini Rev. Med. Chem. 2005, 5(January (1)):57-71. PubMed PMID: 15638792. Epub 2005/01/11. eng.
50. Chagas C. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem. Inst. Oswaldo Cruz 1909, 1(2):159-218.
51. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Ann. Rev. Biochem. 2001, 70(1):369-413. PubMed PMID: 11395412.
52. Choy J.W., Bryant C., Calvet C.M., Doyle P.S., Gunatilleke S.S., Leung S.S., et al. Chemical-biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target. Beilst. J. Org. Chem. 2013, 9(1):15-25.
53. Chung M.-C., Güido R.V.C., Martinelli T.F., Gonçalves M.F., Polli M.C., Botelho K.C.A., et al. Synthesis and in vitro evaluation of potential antichagasic hydroxymethylnitrofurazone (NFOH-121): a new nitrofurazone prodrug. Bioorg. Med. Chem. 2003, 11(22):4779-4783.
54. Cogo J., Kaplum V., Sangi D.P., Ueda-Nakamura T., Corrêa A.G., Nakamura C.V. Synthesis and biological evaluation of novel 2,3-disubstituted quinoxaline derivatives as antileishmanial and antitrypanosomal agents. Eur. J. Med. Chem. 2015, 90:107-123.
55. Corrales M., Cardozo R., Segura M.A., Urbina J.A., Basombrío M.A. Comparative efficacies of TAK-187, a Long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of chagas' disease. Antimicrob. Agents Chemother. 2005, 49(4):1556-1560. PubMed PMID: PMC1068647.
56. Coura J.R. Chagas disease: what is known and what is needed-a background article. Mem. Inst. Oswaldo Cruz 2007, 102:113-122.
57. Coura J.R. The main sceneries of Chagas disease transmission. The vectors, blood and oral transmissions-a comprehensive review. Mem. Inst. Oswaldo Cruz 2015, 110(May (3)):277-282. PubMed PMID: 25466622. Pubmed Central PMCID: PMC4489464. Epub 2014/12/04. eng.
58. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 1998, 1-10.
59. Croft S.L., Barrett M.P., Urbina J.A. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol. 2005, 21(11):508-512.
60. Cunha-Neto E., Chevillard C. Chagas disease cardiomyopathy: immunopathology and genetics. Mediat. Inflamm. 2014, 2014. 683230, PubMed PMID: PMC4152981.
61. Davies C., Cardozo R.M., Negrette O.S., Mora M.C., Chung M.C., Basombrío M.Á. Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease. Antimicrob. Agents Chemother. 2010, 54(9):3584-3589. PubMed PMID: PMC2934987.
62. Davies C., Dey N., Negrette O.S., Parada L.A., Basombrio M.A., Garg N.J. Hepatotoxicity in Mice of a Novel Anti-parasite Drug Candidate Hydroxymethylnitrofurazone: A Comparison with Benznidazole. PLoS Negl. Trop. Dis. 2014, 8(10):e3231. PubMed PMID: PMC4199569.
63. de Mecca M.M., Fanelli S.L., Bartel L.C., de Castro C.R., Díaz E.G., Castro J.A. Nifurtimox nitroreductase activity in different cellular fractions from male rat pancreas. Biochemical and ultrastructural alterations. Life Sci. 2007, 81(2):144-152.
64. De Medeiros M.D.G.F., Da Silva A.C., Citó AMdGL, Borges A.R., De Lima S.G., Lopes J.A.D., et al. In vitro antileishmanial activity and cytotoxicity of essential oil from Lippia sidoides Cham. Parasitol. Int. 2011, 60(3):237-241.
65. Demoro B., Caruso F., Rossi M., Benítez D., Gonzalez M., Cerecetto H., et al. Risedronate metal complexes potentially active against Chagas disease. J. Inorg. Biochem. 2010, 104(12):1252-1258.
66. Dias J.C.P., Coura J.R., Yasuda M.A.S. The present situation, challenges, and perspectives regarding the production and utilization of effective drugs against human Chagas disease. Rev. Soc. Bras. Med. Trop. 2014, 47(1):123-125.
67. Diniz Lde F., Urbina J.A., de Andrade I.M., Mazzeti A.L., Martins T.A., Caldas I.S., et al. Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments. PLoS Negl. Trop. Dis. 2013, 7(8):e2367. PubMed PMID: 23967360. Pubmed Central PMCID: PMC3744424. Epub 2013/08/24. eng.
68. Diniz L.D.F., Caldas I.S., Guedes P.M.D.M., Crepalde G., de Lana M., Carneiro C.M., et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob. Agents Chemother. 2010, 54(7):2979-2986. PubMed PMID: PMC2897273.
69. Estani S.S., Segura E.L., Ruiz A.M., Velazquez E., Porcel B.M., Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am. J. Trop. Med. Hyg. 1998, 59(4):526-529.
70. FDA, Federal Register. 1998.
71. Fauro R., Presti S.L., Bazan C., Baez A., Strauss M., Triquell F., et al. Use of clomipramine as chemotherapy of the chronic phase of Chagas disease. Parasitology 2013, 140(7):917-927.
72. Filardi L., Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans. R. Soc. Trop. Med. Hyg. 1987, 81(5):755-759.
73. Fragoso S.P., Mattei D., Hines J.C., Ray D., Goldenberg S. Expression and cellular localization of Trypanosoma cruzi type II DNA topoisomerase. Mol. Biochem. Parasitol. 1998, 94(2):197-204.
74. Gallerano R.H., Marr J.J., Sosa R.R. Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease. Am. J. Trop. Med. Hyg. 1990, 43(2):159-166.
75. Giorgi M.E., Ratier L., Agusti R., Frasch A.C., de Lederkremer R.M. Synthesis of PEGylated lactose analogs for inhibition studies on T. cruzi trans-sialidase. Glycoconj. J. 2010, 27(5):549-559.
76. Giorgi M.E., Ratier L., Agusti R., Frasch A.C.C., de Lederkremer R.M. Improved bioavailability of inhibitors of Trypanosoma cruzi trans-sialidase: PEGylation of lactose analogs with multiarm polyethyleneglycol. Glycobiology 2012, 22(10):1363-1373. PubMed PMID: PMC3425324.
77. Gonzales-Perdomo M., de Castro S.L., Meirelles M.N., Goldenberg S. Trypanosoma cruzi proliferation and differentiation are blocked by topoisomerase II inhibitors. Antimicrob. Agents Chemother. 1990, 34(9):1707-1714. PubMed PMID: PMC171910.
78. Gorla N.B., Ledesma O.S., Barbieri G.P., Larripa I.B. Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox. Mutat. Res. 1989, 224(2):263-267.
79. Guido R.V.C., Ferreira E.I., Nassute J.C., Varanda E.A., Chung M.C. Diminuiçao da atividade mutagenica do pró-fármaco NFOH-121 emrelaçaoaonitrofural (nitrofurazona). Rev. Cienc. Farm. Sao Paulo 2001, 22:307-318.
80. Hall B.S., Wilkinson S.R. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob. Agents Chemother. 2012, 56(1):115-123.
81. Hall B.S., Bot C., Wilkinson S.R. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J. Biol. Chem. 2011, 286(15):13088-13095.
82. Heindel J, George J, Fail P, Grizzle T. Nitrofurazone. Environ Health Perspect. 1997; 105:331-5.
83. Henderson G.B., Ulrich P., Fairlamb A.H., Rosenberg I., Pereira M., Sela M., et al. Subversive substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. Proc. Natl. Acad. Sci. U. S. A. 1988, 85(15):5374-5378.
84. Hernández P., Rojas R., Gilman R.H., Sauvain M., Lima L.M., Barreiro E.J., et al. Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates. Eur. J. Med. Chem. 2013, 59:64-74.
85. Hiraku Y., Sekine A., Nabeshi H., Midorikawa K., Murata M., Kumagai Y., et al. Mechanism of carcinogenesis induced by a veterinary antimicrobial drug, nitrofurazone, via oxidative DNA damage and cell proliferation. Cancer Lett. 2004, 215(2):141-150.
86. Inahashi Y, Iwatsuki M, Ishiyama A, Matsumoto A, Hirose T, Oshita J, et al. Actinoallolides A-E, New Anti-trypanosomal Macrolides, Produced by an Endophytic Actinomycete, Actinoallomurus fulvus MK10-036. Organic Letters. 2015 2015/02/20; 17(4): 864-7.
87. Iniguez E., Sánchez A., Vasquez M.A., Martínez A., Olivas J., Sattler A., et al. The metal-drug synergy: new ruthenium(ii) complexes of ketoconazole are highly active against leishmania major and Trypanosoma cruzi and non-toxic to human or murine normal cells. J. Biol. Inorg. Chem. 2013, 18(7):779-790. PubMed PMID: PMC3783607.
88. Jimenez V., Kemmerling U., Paredes R., Maya J.D., Sosa M.A., Galanti N. Natural sesquiterpene lactones induce programmed cell death in Trypanosoma cruzi: a new therapeutic target?. Phytomedicine 2014, 21(11):1411-1418.
89. Kim J.H., Ryu H.W., Shim J.H., Park K.H., Withers S.G. Development of new and selective Trypanosoma cruzi trans-sialidase inhibitors from sulfonamide chalcones and their derivatives. ChemBioChem 2009, 10(15):2475-2479.
90. Kubata B.K., Kabututu Z., Nozaki T., Munday C.J., Fukuzumi S., Ohkubo K., et al. A key role for old yellow enzyme in the metabolism of drugs by Trypanosoma cruzi. J. Exp. Med. 2002, 196(9):1241-1252. PubMed PMID: PMC2194105.
91. Lacombe O.K., Zuma A.A., da Silva C.C., de Souza W., Motta M.C.M. Effects of camptothecin derivatives and topoisomerase dual inhibitors on Trypanosoma cruzi growth and ultrastructure. J. Negat. Results Biomed. 2014, 13:11.
92. Leonardi D., Salomón C.J., Lamas M.C., Olivieri A.C. Development of novel formulations for Chagas' disease: Optimization of benznidazole chitosan microparticles based on artificial neural networks. Int. J. Pharm. 2009, 367(1-2):140-147.
93. Lepesheva G.I., Zaitseva N.G., Nes W.D., Zhou W., Arase M., Liu J., et al. CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14α-demethylase. J. Biol. Chem. 2006, 281(February):3577-3585.
94. Lepesheva G.I., Ott R.D., Hargrove T.Y., Kleshchenko Y.Y., Schuster I., Nes W.D., et al. Sterol 14α-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. Chem. Biol. 2007, 14(11):1283-1293.
95. Lima Á.A.N., Soares-Sobrinho J.L., Silva J.L., Corrêa-Júnior R.A.C., Lyra M.A.M., Santos F.L.A., et al. The use of solid dispersion systems in hydrophilic carriers to increase benznidazole solubility. J. Pharm. Sci. 2011, 100(6):2443-2451.
96. Lo Presti M.S., Rivarola H.W., Bustamante J.M., Fernández A.R., Enders J.E., Fretes R., et al. Thioridazine treatment prevents cardiopathy in Trypanosoma cruzi infected mice. Int. J. Antimicrob. Agents 2004, 23(6):634-636.
97. Lo Presti M.S., Bazán P.C., Strauss M., Báez A.L., Rivarola H.W., Paglini-Oliva P.A. Trypanothione reductase inhibitors: overview of the action of thioridazine in different stages of Chagas disease. Acta Trop. 2015, 145:79-87.
98. Lorenzi H, de Abreu Matos FJ. Plantas medicinais no Brasil: nativas e exóticas: Instituto Plantarum de Estudos da Flora; 2002.
99. Lukes J., Trypanosomatida Kent 1880. 2009. Version 02 January 2009 (under construction). Available from: . http://tolweb.org/Trypanosomatida/98015/2009.01.02.
100. Manarin R., Lamas M.C., Bottasso E., Serra E., Revelli S., Salomón C.J. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi. Parasitol. Int. 2013, 62(1):79-81.
101. Martínez A., Carreon T., Iniguez E., Anzellotti A., Sánchez A., Tyan M., et al. Searching for new chemotherapies for tropical diseases: ruthenium-clotrimazole complexes display high in vitro activity against leishmania major and Trypanosoma cruzi and low toxicity toward normal mammalian cells. J. Med. Chem. 2012, 55(8):3867-3877. PubMed PMID: PMC3375397.
102. Martins H., Costa Álves M., Antonelli da Silveira L., Hoffman Pfrimer I., Quadro Andrade S. histopatológico emcamundongos isogénicos C3H/HeJ eC57BL/10 na fase aguda da infeccao com cepas de Trypanosoma cruzi isoladas nas regioes central (Goiás) e Sul (Rio Grande do Sul) do Brasil. Rev. Pat. Trop. 1998, 26(2):189-198.
103. Massarico Serafim R.A., Gonçalves J.E., de Souza F.P., de Melo Loureiro A.P., Storpirtis S., Krogh R., et al. Design, synthesis and biological evaluation of hybrid bioisoster derivatives of N-acylhydrazone and furoxan groups with potential and selective anti-Trypanosoma cruzi activity. Eur. J. Med. Chem. 2014, 82:418-425.
104. Maximiano FP, Hideki Yoshizane Costa Guilherme, Jacqueline dS, Sérgio SdC-FM. CARACTERIZAÇÃO FÍSICO-QUÍMICA DO FÁRMACO ANTICHAGÁSICO BENZNIDAZOL. Quim Nova. 2010; 33: 1714-9.
105. McKerrow J.H., Doyle P., Engel J., Podust L., Robertson S., Ferreira R., et al. Two approaches to discovering and developing new drugs for Chagas disease. Mem. Inst. Oswaldo Cruz 2009, 104:263-269.
106. Mecca MMd, Bartel LC, Castro CRd, Castro JA. Benznidazole biotransformation in rat heart microsomal fraction without observable ultrastructural alterations: comparison to Nifurtimox-induced cardiac effects. Memorias do Instituto Oswaldo Cruz. 2008; 103(6): 549-553.
107. Mejía-Jaramillo A.M., Fernández G.J., Montilla M., Nicholls R.S., Triana-Chávez O. Trypanosoma cruzi strains resistant to benznidazole occurring in Colombia. Biomédica 2012, 32(2):196-205.
108. Melo MFF. Preparaça~o e determinaça~o da atividadetoxicológica do pró-fármaco hidroximetilnitrofural, potencialmente antichagásico. Araraquara, Faculdade de CiênciasFarmacêuticas, UNESP, Sao Paulo, Brazil, 2006.
109. Miller Iii B.R., Roitberg A.E. Design of e-pharmacophore models using compound fragments for the trans-sialidase of Trypanosoma cruzi: screening for novel inhibitor scaffolds. J. Mol. Graph. Model. 2013, 45:84-97.
110. Molina I., Gómez i Prat J., Salvador F., Treviño B., Sulleiro E., Serre N., et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N. Engl. J. Med. 2014, 370(20):1899-1908.
111. Moraes C.B., Giardini M.A., Kim H., Franco C.H., Araujo-Junior A.M., Schenkman S., et al. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Sci. Rep. 2014, 4(4703). PubMed PMID: PMC4004771.
112. Moreira da Silva R., Oliveira L.T., Silva Barcellos N.M., de Souza J., de Lana M. Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method. Antimicrob. Agents Chemother. 2012, 56(6):3344-3348. PubMed PMID: PMC3370797.
113. Morel C., Chiari E., Camargo E.P., Mattei D.M., Romanha A.J., Simpson L. Strains and clones of Trypanosoma cruzi can be characterized by pattern of restriction endonuclease products of kinetoplast DNA minicircles. Proc. Natl. Acad. Sci. U. S. A. 1980, 77(11):6810-6814. PubMed PMID: PMC350379.
114. Morillo C.A., Marin-Neto J.A., Avezum A., Sosa-Estani S., Rassi A., Rosas F., et al. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. New Engl. J. Med. 2015, 373(14):1295-1306.
115. Mucci Juan, Risso Marikena G., Leguizamón Susana M., Frasch Alberto C.C., Oscar C. The trans-sialidase from Trypanosoma cruzi triggers apoptosis by target cell sialylation. Cell. Microbiol. 2006, 8:1086-1095.
116. Murta S.M.F., Gazzinelli R.T., Brener Z., Romanha A.J. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol. Biochem. Parasitol. 1998, 93(2):203-214.
117. Murta S.M.F., dos Santos W.G., Anacleto C., Nirdé P., Moreira E.S.A., Romanha A.J. Drug resistance in Trypanosoma cruzi is not associated with amplification or overexpression of P-glycoprotein (PGP) genes. Mol. Biochem. Parasitol. 2001, 117(2):223-228.
118. Neitz R.J., Chen S., Supek F., Yeh V., Kellar D., Gut J., et al. Lead Identification to Clinical Candidate Selection: Drugs for Chagas Disease. J. Biomol. Screen. 2015, 20(January (1)):101-111.
119. Nogueira Filho M.A., Padilha E.C., Campos M.L., Pontes Machado D.V., Davanco M.G., Pestana K.C., et al. Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits. Drug Metab. Lett. 2013, 7(March (7)):58-64. Epub 2013/08/21. eng.
120. Oliveira R.P., Broude N.E., Macedo A.M., Cantor C.R., Smith C.L., Pena S.D.J. Probing the genetic population structure of Trypanosoma cruzi with polymorphic microsatellites. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(7):3776-3780. PubMed PMID: PMC19913.
121. Oliveira V.C., Moura D.M., Lopes J.A., de Andrade P.P., da Silva N.H., Figueiredo R.C. Effects of essential oils from Cymbopogon citratus (DC) Stapf., Lippiasi and Ocimum gratissimum L. on growth and ultrastructure of Leishmania chagasi promastigotes. Parasitol. Res. 2009, 104(April (5)):1053-1059. PubMed PMID: 19085009. Epub 2008/12/17. eng.
122. Olmo F., Guardia J.J., Marin C., Messouri I., Rosales M.J., Urbanová K., et al. Prospects of an alternative treatment against Trypanosoma cruzi based on abietic acid derivatives show promising results in Balb/c mouse model. Eur. J. Med. Chem. 2015, 89:683-690.
123. PAHO, 2008. Update of American Trypanosomiasis and Leishmaniasis Control and Research: Final Report.
124. Paglini-Oliva P., Rivarola H. Central nervous system agents used as Trypanosoma cruzi infection chemotherapy: phenothiazines and related compounds. Curr. Med. Chem. Anti-Infect. Agents 2003, 2(4):323-333.
125. Papadopoulou M.V., Bloomer W.D., Rosenzweig H.S., Ashworth R., Wilkinson S.R., Kaiser M., et al. Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: in vivo studies. Future Med. Chem. 2013, 5(15):1763-1776. PubMed PMID: PMC3948331.
126. Papadopoulou M.V., Bloomer W.D., Lepesheva G.I., Rosenzweig H.S., Kaiser M., Aguilera-Venegas B., et al. Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents. J. Med. Chem. 2015.
127. Paveto C., Güida M.C., Esteva M.I., Martino V., Coussio J., Flawiá M.M., et al. Anti-Trypanosoma cruzi activity of green tea (Camellia sinensis) catechins. Antimicrob. Agents Chemother. 2004, 48(1):69-74. PubMed PMID: PMC310206.
128. Pearson R.D., Hewlett E.L., Petri W.A. Medical Implications of Molecular Parasitology. Molecular Medical Parasitology 2003, 433-462. Academic Press, London.
129. Pereira K.S., Schmidt F.L., Barbosa R.L., Guaraldo A.M.A., Franco R.M.B., Dias V.L., et al. Transmission of Chagas disease (American Trypanosomiasis) by food. Advances in Food and Nutrition Research 2010, vol. 59:63-85. Academic Press, Chapter 3.
130. Perez-Mazliah D.E., Alvarez M.G., Cooley G., Lococo B.E., Bertocchi G., Petti M., et al. Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study. J. Antimicrob. Chemother. 2013, 68(2):424-437. PubMed PMID: PMC3543119.
131. Pinazo M.-J., Guerrero L., Posada E., Rodríguez E., Soy D., Gascon J. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease. Antimicrob. Agents Chemother. 2013, 57(1):390-395. PubMed PMID: PMC3535922.
132. Pinto Dias J.C. The treatment of Chagas disease (South American trypanosomiasis) treatment of Chagas disease (South American trypanosomiasis). Ann. Intern. Med. 2006, 144(May (10)):772-774. PubMed PMID: 16702594. Epub 2006/05/17. eng.
133. Pinto A.Y., Valente S.A., Valente Vda C., Ferreira A.G., Coura J.R. Acute phase of Chagas disease in the Brazilian Amazon region: study of 233 cases from Para, Amapa and Maranhao observed between 1988 and 2005. Rev. Soc. Bras. Med. Trop. 2008, 41(November-December (6)):602-614. PubMed PMID: 19142440. Epub 2009/01/15. Fase aguda da doenca de Chagas na Amazonia brasileira: estudo de 233 casos do Para, Amapa e Mara nhao observados entre 1988 e 2005. por.
134. Planer J.D., Hulverson M.A., Arif J.A., Ranade R.M., Don R., Buckner F.S. Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi. PLoS Negl. Trop. Dis. 2014, 8(7):e2977. PubMed PMID: PMC4102417.
135. Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem. Biol. 2013, 8(1):82-95.
136. Rassi A., Rassi A., Marin-Neto J.A. Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem. Inst. Oswaldo Cruz 2009, 104:152-158.
137. Rivarola H., Fernandez A., Enders J., Fretes R., Gea S., Paglini-Oliva P. Effects of clomipramine on Trypanosoma cruzi infection in mice. Trans. R. Soc. Trop. Med. Hyg. 2001, 95(5):529-533.
138. Rivarola H.W., Bustamante J.M., Lo Presti S., Fernández A.R., Enders J.E., Gea S., et al. Trypanosoma cruzi: chemotherapeutic effects of clomipramine in mice infected with an isolate obtained from an endemic area. Exp. Parasitol. 2005, 111(2):80-86.
139. Romeiro N.C., Aguirre G., Hernández P., González M., Cerecetto H., Aldana I., et al. Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorg. Med. Chem. 2009, 17(2):641-652.
140. Roque A.L., Xavier S.C., da Rocha M.G., Duarte A.C., D'Andrea P.S., Jansen A.M. Trypanosoma cruzi transmission cycle among wild and domestic mammals in three areas of orally transmitted Chagas disease outbreaks. Am. J. Trop. Med. Hyg. 2008, 79(November (5)):742-749. PubMed PMID: 18981516. Epub 2008/11/05.eng.
141. Rowe D.S. The WHO/UNDP special programme for research and training in tropical diseases. Bull. World Health Org. 1977, 55(2-3):131. PubMed PMID: PMC2366743.
142. Rubin S.S.C., Schenkman S. Trypanosoma cruzi trans-sialidase as a multifunctional enzyme in Chagas disease. Cell. Microbiol. 2012, 14(10):1522-1530.
143. Rubin-de-Celis S.S.C., Uemura H., Yoshida N., Schenkman S. Expression of trypomastigote trans-sialidase in metacyclic forms of Trypanosoma cruzi increases parasite escape from its parasitophorous vacuole. Cell. Microbiol. 2006, 8(12):1888-1898.
144. Sánchez-Valdéz F.J., Pérez Brandán C., Ferreira A., Basombrío MÁ Gene-deleted live-attenuated Trypanosoma cruzi parasites as vaccines to protect against Chagas disease. Exp. Rev. Vaccines 2014, 1-17.
145. Salem M.M., Werbovetz K.A. Natural products from plants as drug candidates and lead compounds against leishmaniasis and trypanosomiasis. Curr. Med. Chem. 2006, 13(21):2571-2598. PubMed PMID: 17017912. Epub 2006/10/05. eng.
146. Sanchez-Delgado R.A., Lazardi K., Rincon L., Urbina J.A., Hubert A.J., Noels A.N. Toward a novel metal-based chemotherapy against tropical diseases. 1. Enhancement of the efficacy of clotrimazole against Trypanosoma cruzi by complexation to ruthenium in RuCl2(clotrimazole) 2. J. Med. Chem. 1993, 36(14):2041-2043.
147. Sandri, P., Aleixo, D.L., Sanchez Falkowski, G.J., Nascimento Jr., G.J., Gomes, M.L., Hernandes, L., et al., 2915. Trypanosoma cruzi: Biotherapy made from trypomastigote modulates the inflammatory response. Homeopathy 104(1); 48-56.
148. Santoro G., Cardoso M., Guimarães L., Freire J., Soares M. Anti-proliferative effect of the essential oil of Cymbopogon citratus (DC) Stapf (lemongrass) on intracellular amastigotes, bloodstream trypomastigotes and culture epimastigotes of Trypanosoma cruzi (Protozoa: Kinetoplastida). Parasitology 2007, 134(11):1649-1656.
149. Santos D., Parajón-Costa B., Rossi M., Caruso F., Benítez D., Varela J., et al. Activity on Trypanosoma cruzi, erythrocytes lysis and biologically relevant physicochemical properties of Pd(II) and Pt(II) complexes of thiosemicarbazones derived from 1-indanones. J. Inorg. Biochem. 2012, 117:270-276.
150. Schenkman S., Eichinger D. Trypanosoma cruzi trans-sialidase and cell invasion. Parasitol. Today 1993, 9(6):218-222.
151. Schenkman S., Jiang M.-S., Hart G.W., Nussenzweig V. A novel cell surface trans-sialidase of Trypanosoma cruzi generates a stage-specific epitope required for invasion of mammalian cells. Cell 1991, 65(7):1117-1125.
152. Serafim E.O.P., Silva A.T.d.A.e., Moreno A.d.H., Vizioli E.d.O., Ferreira E.I., Peccinini R.G., et al., 2013. Pharmacokinetics of Hydroxymethylnitrofurazone, a Promising New Prodrug for Chagas' Disease Treatment. Antimicrob. Agents Chemother. 57(12): 6106-6109. PubMed PMID: PMC3837917.
153. Shikanai-Yasuda M.A., Marcondes C.B., Guedes L.A., Siqueira G.S., Barone A.A., Dias J.C., et al. Possible oral transmission of acute Chagas' disease in Brazil. Rev. Inst. Med. Trop. Sao Paulo 1991, 33(September-October (5)):351-357. PubMed PMID: 1844961. Epub 1991/09/01.eng.
154. Silva J., Morrissey P., Grabstein K., Mohler K., Anderson D., Reed S. Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J. Exp. Med. 1992, 175(1):169-174.
155. Soeiro M.D.N.C., de Souza E.M., da Silva C.F., Batista D.D.G.J., Batista M.M., Pavão B.P., et al. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi. Antimicrob. Agents Chemother. 2013, 57(9):4151-4163. PubMed PMID: PMC3754355.
156. Sturm N.R., Campbell D.A. Alternative lifestyles: the population structure of Trypanosoma cruzi. Acta Trop. 2010, 115(1):35-43.
157. Tagboto S., Townson S. Antiparasitic properties of medicinal plants and other naturally occurring products: advances in parasitology. Adv. Parasitol. 2001, 50:199-295. PubMed PMID: 11757332. Epub 2002/01/05. eng.
158. Takegawa K., Mitsumori K., Yasuhara K., Moriyasu M., Sakamori M., Onodera H., et al. A mechanistic study of ovarian carcinogenesis induced by nitrofurazone using rasH2 mice. Toxicol. Pathol. 2000, 28(5):649-655.
159. Tarragona Sonia, Salomón Claudio, Jiménez-Kairuz Álvaro, Lamas María, Orlandi Silvina, Leonardi Darío, et al. Design and Preparation of pharmaceutical solid dosage forms of benznidazole for the treatment of chagas disease. Rev. Argent. Salud Pública 2013.
160. Tepe B., Sokmen A. Screening of the antioxidative properties and total phenolic contents of three endemic Tanacetum subspecies from Turkish flora. Bioresour. Technol. 2007, 98(16):3076-3079. PubMed PMID: 17157500. Epub 2006/12/13. eng.
161. Tibayrenc M., Breniere S.F. Trypanosoma cruzi: major clones rather than principal zymodemes. Mem. Inst. Oswaldo Cruz 1988, 83:249-255.
162. Tibayrenc M., Ward P., Moya A., Ayala F.J. Natural populations of Trypanosoma cruzi, the agent of Chagas disease, have a complex multiclonal structure. Proc. Natl. Acad. Sci. U. S. A. 1986, 83(1):115-119. PubMed PMID: PMC322802.
163. Tibayrenc M., Neubauer K., Barnabe C., Guerrini F., Skarecky D., Ayala F.J. Genetic characterization of six parasitic protozoa: parity between random-primer DNA typing and multilocus enzyme electrophoresis. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(4):1335-1339.
164. Tibayrenc M. Genetic subdivisions within Trypanosoma cruzi (Discrete Typing Units) and their relevance for molecular epidemiology and experimental evolution. Kinet. Biol. Dis. 2003, 2:12. PubMed PMID: PMC270070.
165. Toledo MJdO, Bahia MT, Carneiro CM, Martins-Filho OA, Tibayrenc M, Barnabé C, et al. Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes. Antimicrobial Agents and Chemotherapy. 2003; 47(1): 223-30.
166. Toledo M., Bahia M., Veloso V., Carneiro C., Machado-Coelho G., Alves C., et al. Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypes. J. Antimicrob. Chemother. 2004, 53(6):1045-1053.
167. Trischmann T.M., Bloom B.R. Genetics of murine resistance to Trypanosoma cruzi. Infect. Immun. 1982, 35(2):546-551. PubMed PMID: PMC351075.
168. Trochine A., Creek D.J., Faral-Tello P., Barrett M.P., Robello C. Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics. PLoS Negl. Trop. Dis. 2014, 8(5):e2844. PubMed PMID: PMC4031082.
169. Trossini G.H.G., Malvezzi A., -do Amaral T.A., Rangel-Yagui C.O., Izidoro M.A., Cezari M.H.S., et al. Cruzain inhibition by hydroxymethylnitrofurazone and nitrofurazone: investigation of a new target in Trypanosoma cruzi. J. Enzyme Inhib. Med. Chem. 2010, 25(1):62-67. PubMed PMID: 20030510.
170. Urbina J.A., Payares G., Sanoja C., Lira R., Romanha A.J. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents 2003, 21(1):27-38.
171. Urbina J.A. Recent clinical trials for the etiological treatment of chronic Chagas disease: advances, challenges and perspectives. J. Eukaryotic Microbiol. 2015, 62(1):149-156.
172. Vázquez-Chagoyán J.C., Gupta S., Garg N.J. Vaccine development against Trypanosoma cruzi and Chagas disease. Advances in Parasitology 2011, vol. 75:121-146. Academic Press, Chapter 6.
173. Vassena C.V., Picollo M.I. Monitoreo de resistencia a insecticidas en poblaciones de campo de Triatoma infestans y Rhodnius prolixus, insectos vectores de la Enfermedad de Chagas. Rev. Toxicol. Línea 2003, 3:1-21.
174. Veiga-Santos P., Li K., Lameira L., de Carvalho T.M.U., Huang G., Galizzi M., et al. SQ109: a new drug lead for chagas disease. Antimicrob. Agents Chemother. 2015.
175. Villela E, Villela E. Von. Trypanosoma Cruzi befallene Bestandteile des Zentralnervensystems. Z f d g Neur u Psych. 1933 1933/12/01; 144(1): 155-60. German.
176. Viotti R., Vigliano C., Armenti H., Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am. Heart J. 1994, 127(1):151-162.
177. Viotti R., Vigliano C., Álvarez M.G., Lococo B., Petti M., Bertocchi G., et al. Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS Negl. Trop. Dis. 2011, 5(9):e1314. PubMed PMID: PMC3167788.
178. Viotti R., Alarcón de Noya B., Araujo-Jorge T., Grijalva M.J., Guhl F., López M.C., et al. Towards a paradigm shift in the treatment of chronic chagas disease. Antimicrob. Agents Chemother. 2014, 58(2):635-639. PubMed PMID: PMC3910900.
179. WHO Control of Chagas Disease: Second Report of the WHO Expert Committee 2002, WHO, 905.
180. WHO Sustaining the Drive to Overcome the Global Impact of Neglected Tropical Diseases: Second Who Report on Neglected Diseases 2013, WHO.
181. Wang X, Sun H. Metal Complexes in the Treatment of Tropical Diseases: Malaria, Trypanosomiasis, and Leishmaniasis. Comprehensive inorganic chemistry II: from elements to applications (2nd ed). 2013;3:975-86.
182. Watts A.G., Damager I., Amaya M.L., Buschiazzo A., Alzari P., Frasch A.C., et al. Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: tyrosine is the catalytic nucleophile. J. Am. Chem. Soc. 2003, 125(25):7532-7533.
183. Weiss Louis M., Tanowitz Herbert B., V. KL. Advances in parasitology Ltd E, editor, 2011.
184. Wilkinson S.R., Taylor M.C., Horn D., Kelly J.M., Cheeseman I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(13):5022-5027.
185. Wilkinson R., Bot S., Kelly M., Hall S. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. Curr. Top. Med. Chem. 2011, 11(16):2072-2084.
186. Williams-Blangero S., Criscione C.D., VandeBerg J.L., Correa-Oliveira R., Williams K.D., Subedi J., et al. Host genetics and population structure effects on parasitic disease. Philos. Trans. R. Soc. B 2012, 367(1590):887-894.
187. Wood S.F. A new locality for Trypanosoma cruzi Chagas in California. Science 1938, 87(2260):366-367.
188. Yoshida N. Molecular mechanisms of Trypanosoma cruzi infection by oral route. Mem. Inst. Oswaldo Cruz 2009, 104(July (Suppl. 1)):101-107. PubMed PMID: 19753464. Epub 2009/09/24. eng.
189. Zingales B., Andrade S., Briones M., Campbell D., Chiari E., Fernandes O., et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem. Inst. Oswaldo Cruz 2009, 104:1051-1054.
190. Zingales B., Miles M.A., Moraes C.B., Luquetti A., Guhl F., Schijman A.G., et al. Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity. Mem. Inst. Oswaldo Cruz 2014, 109(6):828-833. PubMed PMID: PMC4238778.
191. Zuma A.A., Mendes I.C., Reignault L.C., Elias M.C., de Souza W., Machado C.R., et al. How Trypanosoma cruzi handles cell cycle arrest promoted by camptothecin, a topoisomerase I inhibitor. Mol. Biochem. Parasitol. 2014, 193(2):93-100.
192. Zuma A.A., Cavalcanti D.P., Maia M.C.P., de Souza W., Motta M.C.M. Effect of topoisomerase inhibitors and DNA-binding drugs on the cell proliferation and ultrastructure of Trypanosoma cruzi. Int. J. Antimicrob. Agents 2015, 37(5):449-456.